Afinitor (everolimus) vs Lumakras (sotorasib)

Afinitor (everolimus) and Lumakras (sotorasib) are both targeted therapies used in cancer treatment but they act on different pathways within cancer cells. Afinitor is an mTOR inhibitor, which is used in various types of cancer, such as breast, kidney, and neuroendocrine tumors, and works by disrupting cell growth and proliferation. Lumakras, on the other hand, is a KRAS G12C inhibitor indicated specifically for the treatment of non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, targeting a specific genetic mutation to halt cancer progression. For someone deciding on which medicine is right for them, the choice would largely depend on the specific type and genetic characteristics of their cancer, as well as their overall health, and should be made in consultation with their oncologist.

Difference between Afinitor and Lumakras

Metric	Afinitor (everolimus)	Lumakras (sotorasib)
Generic name	Everolimus	Sotorasib
Indications	Advanced hormone receptor-positive, HER2-negative breast cancer, advanced neuroendocrine tumors, renal cell carcinoma, tuberous sclerosis complex, and subependymal giant cell astrocytoma	Non-small cell lung cancer (NSCLC) with KRAS G12C mutation
Mechanism of action	mTOR inhibitor, which inhibits cell proliferation, angiogenesis, and glucose uptake	KRAS G12C inhibitor, selectively targeting the KRAS G12C mutation and inhibiting cancer cell growth
Brand names	Afinitor, Afinitor Disperz, Zortress	Lumakras
Administrative route	Oral	Oral
Side effects	Mouth ulcers, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, pneumonitis	Diarrhea, musculoskeletal pain, nausea, fatigue, liver enzyme elevation, cough, abdominal pain
Contraindications	Hypersensitivity to everolimus or other rapamycin derivatives	Hypersensitivity to sotorasib or any of its excipients
Drug class	mTOR inhibitor	KRAS G12C inhibitor
Manufacturer	Novartis	Amgen

Efficacy

Efficacy of Afinitor (Everolimus) in Lung Cancer

Afinitor (everolimus) is a medication that is primarily used to treat various types of cancer by inhibiting the mammalian target of rapamycin (mTOR), a protein that regulates cell growth, proliferation, and survival. In the context of lung cancer, everolimus has been studied for its efficacy in non-small cell lung cancer (NSCLC), particularly in patients who have progressed after prior treatments. The efficacy of Afinitor in lung cancer has been shown to be modest, with some studies indicating a benefit in terms of progression-free survival, especially in patients with specific genetic alterations or in combination with other therapies. However, it is not commonly used as a first-line treatment for lung cancer.

It is important to note that the use of everolimus in lung cancer may be more prevalent in certain subtypes of NSCLC or in a research setting. Clinical trials continue to explore its efficacy and safety profile in combination with other drugs or as a part of targeted therapy regimens. The results from these studies will further elucidate the role of Afinitor in treating lung cancer.

Efficacy of Lumakras (Sotorasib) in Lung Cancer

Lumakras (sotorasib) represents a significant advancement in the treatment of lung cancer, specifically for patients with NSCLC harboring the KRAS G12C mutation. This mutation has historically been considered "undruggable," but sotorasib has emerged as the first targeted therapy to show clinical efficacy against this specific genetic alteration. In clinical trials, Lumakras has demonstrated a notable response rate in patients with KRAS G12C-mutated NSCLC who have previously received systemic therapy. The drug has shown to shrink tumors and provide a durable response, making it a promising option for this subset of lung cancer patients.

As of the knowledge cutoff date, Lumakras has received approval from regulatory agencies, including the U.S. Food and Drug Administration (FDA), for the treatment of patients with KRAS G12C-mutated NSCLC. The approval was based on the results of a Phase 2 clinical trial that showed significant efficacy in terms of response rate and disease control. Ongoing research and additional clinical trials are expected to further define the optimal use of Lumakras in lung cancer treatment, including potential combinations with other therapies to enhance its efficacy.

Regulatory Agency Approvals

Afinitor

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Lumakras

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom

Access Afinitor or Lumakras today

If Afinitor or Lumakras are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Afinitor

Buy Lumakras

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: